Stay updated on ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial
Sign up to get notified when there's something new on the ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial page.

Latest updates to the ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedMajor update: page now includes a government funding status notice and indicates version 3.2.0, replacing the previous 3.1.0.SummaryDifference3%
- Check16 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0; no substantive content changes detected.SummaryDifference0.1%
- Check23 days agoNo Change Detected
- Check30 days agoChange Detected- Updated page revision from v3.0.0 to v3.0.2. No other substantive content changes detected.SummaryDifference0.1%
- Check45 days agoChange DetectedThe web page has undergone significant updates, including the addition of new therapeutic techniques and the removal of specific disease-related resources and terms.SummaryDifference2%
- Check59 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
- Check66 days agoChange DetectedThe web page has been updated from version v2.16.10 to v2.16.11.SummaryDifference0.1%
Stay in the know with updates to ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial page.